The Rho Associated Protein Kinase 1 pipeline drugs market research report outlays comprehensive information on the Rho Associated Protein Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Rho Associated Protein Kinase 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Respiratory, Non Malignant Disorders, and Gastrointestinal which include the indications Oncology, Breast Cancer, Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Crohn’s Disease (Regional Enteritis), and Liver Fibrosis. It also reviews key players involved in Rho Associated Protein Kinase 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Rho Associated Protein Kinase 1 pipeline targets constitutes close to 14 molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/ CTA Filed, and Preclinical stages are 1, 1, and 7 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 2 molecule.
Rho Associated Protein Kinase 1 overview
Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.
For a complete picture of Rho Associated Protein Kinase 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
